Y-mAbs Therapeutics Inc (NAS:YMAB)
$ 12.31 -0.42 (-3.3%) Market Cap: 540.19 Mil Enterprise Value: 484.06 Mil PE Ratio: 0 PB Ratio: 5.45 GF Score: 56/100

Q1 2022 Y-mAbs Therapeutics Inc Earnings Call Transcript

May 10, 2022 / 01:00PM GMT
Release Date Price: $10.03 (+22.02%)
Operator

Good day, and welcome to the Y-mAbs Therapeutics, Inc.'s Earnings Conference Call for the First Quarter of 2022. Today's conference is being recorded.

Let me quickly remind you that the following discussion contains certain forward-looking -- certain statements that are considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Because forward-looking statements involve risks and uncertainties, they are not guarantees of future performance and actual results may differ materially from those expressed or implied by these forward-looking statements due to a variety of factors, including those risk factors discussed in the company's annual report on the Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on March 1, 2022.

At this time, I would now like to turn the conference over to Thomas Gad, the company's Founder, Interim CEO and President.

Thomas Gad
Y-mAbs Therapeutics, Inc. - Founder, Interim CEO, President, Head of Business Development & Strategy and Director

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot